About: Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $9.33 (-6.14%)
SGMT NASDAQ Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc. Series A Common Stock share price
SGMT price activity
Last Price
$9.330
Change (24hr)
-0.61 USD (-6.14%)
Volume
778.45K
Volume (4w avg)
-
Open
$9.92
Day Range
$9.25 - $9.92
Previous Close
$9.94
Last Trade
29 Sep, 8:28 pm GMT+0
Delayed
29 Sep, 8:28 pm GMT+0
SGMT price performance
Delayed
29 Sep, 8:28 pm GMT+0
SGMT Market Signals